| Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual … A Bataller, G Oñate, M Diaz‐Beyá, F Guijarro, A Garrido, S Vives, ... British Journal of Haematology 191 (1), 52-61, 2020 | 35 | 2020 |
| European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol A Bataller, A Garrido, F Guijarro, G Oñate, M Diaz-Beyá, M Arnan, ... Blood advances 6 (4), 1193-1206, 2022 | 27 | 2022 |
| Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1 G Oñate, A Bataller, A Garrido, M Hoyos, M Arnan, S Vives, R Coll, ... Blood Advances 6 (3), 882-890, 2022 | 16 | 2022 |
| Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges S Redondo, A Esquirol, S Novelli, AC Caballero, A Garrido, G Oñate, ... Transplantation and Cellular Therapy 28 (1), 43. e1-43. e5, 2022 | 11 | 2022 |
| Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort G Oñate, M Pratcorona, A Garrido, A Artigas-Baleri, A Bataller, M Tormo, ... Blood Cancer Journal 13 (1), 69, 2023 | 5 | 2023 |
| Ultrastructural, cytogenetic, and molecular findings in mast cell leukemia: Case report A Bosch‐Vilaseca, A Monter‐Rovira, S Cisa‐Wieczorek, G Oñate, ... Clinical case reports 7 (7), 1395-1398, 2019 | 3 | 2019 |
| Adquisición de la inv (16)(p13q22) en un caso de crisis blástica de leucemia mieloide crónica en tratamiento con imatinib G Oñate, ML Blanco, M Pratcorona Medicina Clínica 152 (10), 419-420, 2019 | 2 | 2019 |
| Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide … I García-Cadenas, S Redondo, A Esquirol, JM Portos, S Novelli, ... Transplantation and Cellular Therapy 29 (7), 473. e1-473. e6, 2023 | 1 | 2023 |
| Outcome Improvement Over Time in Reduced Intensity Conditioning Hematopoietic Transplantation: A 20 Years Experience A Esquirol, I García-Cadenas, S Novelli, A Garrido, AC Caballero, ... | 1 | 2023 |
| Sequence matters: Total body irradiation (TBI)‐based myeloablative conditioning with post‐transplant cyclophosphamide may reduce the early nonrelapse mortality compared with … S Redondo, I García‐Cadenas, A Vila, A Esquirol, JM Portos, S Novelli, ... European Journal of Haematology, 2023 | | 2023 |
| Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1 (vol 6, pg 882, 2022) G Onate, A Bataller, A Garrido BLOOD ADVANCES 7 (5), 875-875, 2023 | | 2023 |
| P385: DETECTION OF KMT2A PARTIAL TANDEM DUPLICATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS BY NGS A Artigas-Baleri, G Oñate, A Brell, J Esteve, S Vives, M Tormo, M Arnan, ... HemaSphere 6, 285-286, 2022 | | 2022 |
| P565: IMPROVED OUTCOME OF PATIENS WITH ACUTE MYELOID LEUKEMIA HARBORING FLT3 MUTATION IN THE ERA OF TARGETED THERAPY G Oñate, M Pratcorona, A Garrido, A Artigas, A Bataller, M Tormo, ... HemaSphere 6, 464-465, 2022 | | 2022 |
| European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol A Bataller Torralba, A Garrido, F Guijarro, G Oñate, M Díaz-Beyá, M Arnan, ... American Society of Hematology, 2022 | | 2022 |
| European LeukemiaNet 2017 risk stratification for acute myeloid leukemia A Bataller, A Garrido, F Guijarro, G Oñate, M Díaz-Beyá, M Arnan, ... | | 2022 |
| Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012) A Bataller, A Garrido, F Guijarro, M Diaz-Beyá, G Oñate, M Hoyos, ... Blood 136, 31-32, 2020 | | 2020 |
| ACUTE MYELOID LEUKAEMIA AT ADVERSE RISK (EUROPEAN LEUKEMIANET): IDENTIFICATION OF A SUBGROUP OF PATIENTS WITH A VERY UNFAVORABLE PROGNOSIS A Bataller, A Garrido, F Guijarro, M Diaz-Beya, G Onate, M Tormo, ... HAEMATOLOGICA 105, 51-51, 2020 | | 2020 |
| ANALYSIS OF THE INFLUENCE OF DNMT3A ON MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA WITH MUTATION OF NPM1 G Onate, A Bataller, A Garrido, J Esteve, M Arnan, S Vives, R Coll, ... HAEMATOLOGICA 104, 267-267, 2019 | | 2019 |
| PB2065 DIAGNOSTIC VALUE OF THE NEW SYSMEX XN 2000 AUTOANALIZER IN THE STUDY OF LYMPHOCYTOSIS F Díaz, R Awol, G Onate, M Sabtaliestra, A Remacha HemaSphere 3 (S1), 931, 2019 | | 2019 |
| PS995 IMPACT OF DNMT3A MUTATIONAL STATUS IN MOLECULAR MEASURABLE RESIDUAL DISEASE CLEARANCE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 G Oñate, A Bataller, A Garrido, J Esteve, M Arnan, S Vives, R Coll, ... HemaSphere 3 (S1), 447-448, 2019 | | 2019 |
Jorge SierraHematology Department, Hospital Santa Creu i Sant Pau, Universitat Autònoma de BarcelonaVerified email at santpau.cat
